Loading
Life sciences · Journal article
The Journal of Dermatology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Nationwide prospective data on the clinical management of cutaneous angiosarcoma in Japan are lacking. We analyzed 3 years of data from the Japan Skin Cancer Registry Study, a registry involving 86 institutions. Analyses were restricted to the 335 patients registered at least 12 months before the follow-up data cutoff, a criterion independent of outcome. The median age was 79 years, 66.6% were male, and 74.0% of lesions were located on the scalp. The median tumor diameter was 8.0 cm. At diagnosis, lymph node and distant metastases were present in 14.0% and 12.5%, respectively. Radiotherapy was administered to 78.8%, systemic therapy to 72.8%, and surgery to 14.6%. The most common treatment combination was radiotherapy plus systemic therapy without surgery (54.6%). Median overall survival was 29.0 months, with 1- and 2-year survival rates of 73.8% and 54.8%, respectively. Overall survival was 33.0 months without metastasis, 20.0 months with lymph node metastasis, and 10.0 months with distant metastasis. Distant metastasis (hazard ratio 2.66; 95% confidence interval 1.63-4.33), tumor diameter (1.70 per unit of log-transformed diameter; 1.30-2.22), and age (1.03 per year; 1.01-1.05) were independent prognostic factors; lymph node metastasis (1.59; 0.96-2.61) and male sex (1.46; 0.96-2.22) were not. Two-year overall survival was higher in the surgery group (81.5% vs. 49.6%), but was no longer statistically significant after 1:1 propensity score matching (79.7% vs. 61.6%; hazard ratio 0.53; 0.24-1.20), although survival remained numerically higher in the surgery group. The objective response rate to systemic therapy declined from 57.7% in the first line to 23.0% in the second line and 6.7% in the third line. In Japan, cutaneous angiosarcoma is most commonly managed with radiotherapy and taxane-based systemic therapy rather than surgery. The survival advantage in the unadjusted analysis may partly reflect imbalances in background factors and selection of patients with a favorable prognosis for surgery.